Pierre A. MORGON is CEO of MRGN Advisors, Executive Vice President, Portfolio Strategy and Supranational Affairs, and Managing Director Europe at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners.

He is Chairman of the Boards of Eurocine Vaccines, MYCB1, Kupando and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells, Amoeba and Limula.

Pierre has over 35 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.

He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is a mentor for start-up life sciences companies.

He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, and he is an alumnus of INSEAD and IMD